Pharmaceutical Technology

NOVEMBER 16, 2022

Under the deal, the LentiPeak lentiviral vector technology platform and cell therapy production expertise of ElevateBio BaseCamp will be used by Affini-T to develop its investigational oncogenic driver programmes in the clinic. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Development 246

Development Gene Therapy Engineer Gene Editing 246

Pharmaceutical Technology

MARCH 20, 2023

RVAC Medicines has announced a research collaboration with the University of Pennsylvania (Penn) for the discovery and development of mRNA vaccines. The mRNA vaccine candidates will help reduce the chances of autoimmune responses that might lead to allergic conditions or serious autoimmune diseases.

Vaccination 245

Vaccination Vaccine Development Allergies 245

BioPharma Reporter

OCTOBER 11, 2022

Intranasal delivery of ChAdOx1 nCoV-19 failed to induce either a consistent mucosal antibody response or a strong systemic immune response, according to results from a Phase 1 clinical trial released today.

Immune Response 116

Immune Response Vaccination Vaccine Clinical Trials 116

BioSpace

DECEMBER 10, 2020

The COVID-19 vaccine candidate developed by Sanofi and GlaxoSmithKline hit a snag that will delay the launch of a Phase III study due to an insufficient immune response in older trial patients.

Immune Response 95

Immune Response Vaccination Vaccine Trials 95

Medical Xpress

JANUARY 4, 2023

In a new study by researchers from Mass General Brigham's founding members, Brigham and Women's Hospital and Massachusetts General Hospital, a team extensively investigated the immune response of 16 adolescents and young adults who developed myocarditis after receipt of the COVID mRNA vaccine.

Immune Response 90

Immune Response Protein Vaccination Vaccine 90

pharmaphorum

SEPTEMBER 7, 2020

A trial of Russia’s Sputnik V coronavirus vaccine has shown the jab produces an immune response, although the study was too small to produce conclusive findings, particularly on safety. But there are concerns that Russia has rushed development of the vaccine to claim a political victory in the race to get a vaccine approved.

Immune Response 107

Immune Response Vaccination Vaccine Trials 107

Pharmaceutical Technology

OCTOBER 6, 2022

BioLink Life Sciences has received a contract worth $750,000 from the US Biomedical Advanced Research and Development Authority (BARDA) to develop Ramatroban for treating Covid-19 pneumonia patients in the hospital setting.

Development 162

Development Life Science Immune Response Trials 162

Scienmag

JULY 12, 2021

Scientists have produced the first fine-detail molecular blueprints of a bacterial enzyme known as Lit, which is suspected to play a “stealthy” role in the progression of infection by reducing the immune response.

Immune Response 75

Immune Response Scientist Development Drugs 75

Pharma Mirror

NOVEMBER 30, 2020

Chippenham, UK: Vectura Group plc, an industry leading inhalation CDMO, today announces that it has signed a global out licence and development agreement with Kinaset Therapeutics Inc. for the development and commercialisation of VR588, a preclinical novel inhaled pan-JAK inhibitor for the prevention and treatment of severe asthma.

Development 130

Development Immune Response Clinical Trials Clinical Trials 130

Pharmaceutical Technology

OCTOBER 6, 2022

from the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to develop a prophylactic intranasal vaccine against Neisseria gonorrhoeae (NG). Leveraging its outer membrane vesicles (OMV) platform technology, Intravacc will develop the vaccine.

Vaccination 147

Vaccination Vaccine Development Bacterium 147

Worldwide Clinical Trials

OCTOBER 14, 2024

Given the complexity and widespread impact of autoimmune and bone health conditions, developing new therapies is essential. For instance, drugs like belimumab, a monoclonal antibody, have shown promise in treating systemic lupus erythematosus and lupus nephritis by reducing the overactive immune response.

Research 147

Research Clinical Trials Clinical Trials Immune Response 147

Medical Xpress

APRIL 12, 2023

Testing the efficacy of a vaccine candidate is typically a long process, with the immune response of an animal model taking around two months.

Vaccination 121

Vaccination Vaccine Immune Response Development 121

Worldwide Clinical Trials

OCTOBER 14, 2024

Given the complexity and widespread impact of autoimmune and bone health conditions, developing new therapies is essential. For instance, drugs like belimumab, a monoclonal antibody, have shown promise in treating systemic lupus erythematosus and lupus nephritis by reducing the overactive immune response.

Research 130

Research Clinical Trials Clinical Trials Immune Response 130

Pharmaceutical Technology

MAY 22, 2023

It can suppress Th2 immune responses by binding to IL-17RB on Type 2 innate lymphoid cells (ILC2s). This blocks a cascade of responses that are induced by interleukin-25 (IL-25), a critical cytokine which is classified as ‘alarmin’. “As

Immune Response 273

Immune Response Clinical Trials Clinical Trials Antibody 273

Scienmag

APRIL 16, 2021

Credit: (C) Erica Tandori Researchers within the Biomedicine Discovery Institute at Monash University have made a breakthrough in understanding the role played by high-risk immune genes associated with the development of rheumatoid arthritis (RA).

Immune Response 97

Immune Response Gene Research Development 97

Camargo

DECEMBER 13, 2021

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. One common characteristic for most if not all biologics is the triggering of an immune response or anti-drug antibodies.

Development 161

Development Production Immune Response Licensing 161

Pharmaceutical Technology

APRIL 5, 2023

Absci has collaborated with bioinformatics firm M2GEN to expedite the development of new cancer medicines. Absci stated that this collaboration combines AI drug creation technology and oncology bioinformatics, thereby reducing the time and cost of cancer drug development.

Development 130

Development Bioinformatics Drugs Immune Response 130

Pharmaceutical Technology

DECEMBER 6, 2022

Evaxion Biotech and ExpreS 2 ion Biotechnologies have entered a vaccine discovery collaboration agreement to co-develop a new cytomegalovirus (CMV) vaccine candidate. Additionally, this project will be part of the development pipeline of Evaxion under EVX-V1. Evaluations will follow this method in preclinical models of Evaxion.

Vaccination 130

Vaccination Vaccine Development Immune Response 130

Pharmaceutical Technology

MAY 12, 2023

Absci has collaborated with the University of Oxford’s Kennedy Institute of Rheumatology to expedite the development of AI-driven immunotherapies. The company will then reassemble the antigen-antibody pairs, using its reverse immunology approach, as starting points for the development of drugs.

Development 130

Development Antibody Immune Response Genomics 130

Pharmaceutical Technology

APRIL 28, 2023

Biotechnology company Therini Bio has raised $36m in a Series A financing round to develop fibrin-targeted therapies to treat neurodegenerative and retinal diseases. THN391 binds the inflammation-driving component of fibrin, known for activating the immune responses in neurodegenerative and ophthalmologic diseases.

Development 130

Development Immune Response Clinical Trials Clinical Trials 130

XTalks

APRIL 1, 2025

We are thrilled with the results from the EQUATOR study, which mark a major milestone in the development of itolizumab as a first-line treatment option for aGVHD, said Bruce Steel, CEO of Equillium, in the companys news release.

Immune Response 94

Immune Response Trials Licensing Licensing 94

BioSpace

AUGUST 13, 2020

A COVID-19 vaccine candidate developed by Chinese pharmaceutical company Sinopharm triggered antibody-based immune responses in early and mid-stage trials.

Immune Response 132

Immune Response Vaccination Vaccine Antibody 132

BioPharma Reporter

DECEMBER 11, 2020

Sanofi and GSK announced a delay on Friday in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly, saying clinical trials showed an insufficient immune response in older people.

Immune Response 105

Immune Response Vaccination Vaccine Trials 105

BioPharma Reporter

JANUARY 25, 2021

Merck is shutting down the programs linked to its two COVID-19 vaccine candidates following early trial data indicating that they failed to generate immune responses comparable to a natural infection or existing vaccines.

Vaccination 98

Vaccination Vaccine Immune Response Development 98

Pharmaceutical Technology

FEBRUARY 13, 2023

According to the GlobalData Pharma Intelligence Center, there are currently 71 PROTACs in development in the oncology pipeline by non-academic developers, mostly clustering in the preclinical and discovery phases, with only 14 agents in clinical stages.

Development 147

Development Protein Immune Response Trials 147

Pharmaceutical Technology

JUNE 23, 2022

According to findings from a pivotal study, a four-dose paediatric regimen of Vaxneuvance induced immune responses non-inferior to the presently available 13-valent pneumococcal conjugate vaccine (PCV13) for the 13 shared serotypes.

Vaccination 147

Vaccination Vaccine Immune Response Clinical Trials 147

Pharmaceutical Technology

FEBRUARY 15, 2023

New generation of monoclonal antibodies (bi-specific antibodies) are considered active immunotherapies because they link immune cells and cancer cells to activate anti-cancer immune response. Immatics undertakes the discovery of targets for cancer immunotherapies with the development of the right T-cell receptors.

Antibody 261

Antibody Immune Response Protein Development 261

BioSpace

DECEMBER 2, 2021

IDRI is working with a newly-formed consortium to develop a next-gen COVID-19 vaccine that will be stable at routine temperatures and that may be able to confer immunity for a longer duration.

Immune Response 76

Immune Response Vaccination Vaccine Development 76

Drug Patent Watch

DECEMBER 9, 2024

The Role of Analytical Characterization Analytical characterization is a critical step in the development of biosimilars. Additionally, the immunogenicity of biosimilars, which is the ability of the drug to trigger an immune response, can be highly variable and impact the safety and efficacy of the drug. References Bilea, A.

Clinical Trials 96

Clinical Trials Clinical Trials Immune Response Production 96

Scienmag

APRIL 1, 2021

Early life exposure to antibotics in utero and through mother’s milk disrupts beneficial gut bacteria, compromising T-cell development, Rutgers research shows Exposure to antibiotics in utero and infancy can lead to an irreversible loss of regulatory T-cells in the colon-a valuable component of the immune system’s response toward allergens (..)

Immune Response 75

Immune Response Allergies Bacteria Development 75

Scienmag

JUNE 21, 2022

PHILADELPHIA — (June 21, 2022) — Due to the development of resistance to chemotherapy and recurring tumors, patients with ovarian cancer often have low survival rates. Therefore, new therapeutic options such as targeted therapy that boosts antitumor immunity are needed to improve ovarian cancer treatment efficacy and patient survival.

Immune Response 81

Immune Response Scientist Development 81

pharmaphorum

JULY 18, 2022

It then elicits an immune response against that spike protein. You have a response with immunoglobulins type G (antibodies) and robust cellular response with both CD4 and CD8 T-cells being activated,” Morgon states. We get a higher immune response with the inhaled compared to the injectable,” Morgon relays.

Vaccination 138

Vaccination Vaccine Development Immune Response 138

Scienmag

OCTOBER 13, 2021

Researchers from the Institute of Process Engineering (IPE) of the Chinese Academy of Sciences have developed macrophage–tumor chimeric exosomes that co-activate the immune response and tumor microenvironment to support cancer immunotherapy.

Immune Response 52

Immune Response Engineer Development Research 52

Pharmaceutical Technology

JUNE 16, 2023

The developer has tested OVX836 in four completed clinical trials. In a company statement announcing the latest trial kick-off, Osivax said a recently completed separate Phase IIa trial demonstrated that the candidate in combination with QIVs had a good safety profile with no impairment of immune response by the QIVs.

Vaccination 246

Vaccination Vaccine Trials Immune Response 246

STAT News

NOVEMBER 2, 2022

startup — whose name is a portmanteau of “vaccine” and “access” — has inched toward the creation of a vaccine that’s easy to use, doesn’t require refrigeration, and releases slowly in the skin for a stronger immune response. For more than a decade, the Cambridge, Mass.,

Vaccination 105

Vaccination Vaccine Immune Response Development 105

XTalks

NOVEMBER 15, 2024

MDS are a group of blood disorders caused by abnormal development of blood cells in the bone marrow. This progression occurs when the abnormal cells in the bone marrow increase uncontrollably, leading to the development of a more aggressive form of blood cancer. “We

Trials 105

Trials HR Immune Response FDA Approval 105

The Pharma Data

JULY 29, 2021

Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Kumquat Biosciences today announced an exclusive collaboration focused on the discovery, development and commercialization of potential novel small molecules that stimulate tumor-specific immune responses.

Immune Response 52

Immune Response Development Medicine Drugs 52